BIOXCEL THERAPEUT
BIOXCEL THERAPEUT
Share · US09075P1057 · BTAI · A2JF20 (LSSI)
Overview Financial Indicators
1,68 EUR
1,59 % 0,03 EUR
Lang & Schwarz (XNAS) · Current prices and charts at MoneyPeak
10.06.2025 08:01

Current Prices from BIOXCEL THERAPEUT

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
BTAI
USD
10.06.2025 08:01
1,92 USD
1,96 USD
-2,04 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
1,55 % 41,39 % 25,36 % -43,73 % -76,76 % -92,03 % -99,76 %

Company Profile for BIOXCEL THERAPEUT Share

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Company Data

Name BIOXCEL THERAPEUT
Company BioXcel Therapeutics, Inc.
Symbol BTAI
Website https://www.bioxceltherapeutics.com
Primary Exchange LSSI Lang & Schwarz
WKN A2JF20
ISIN US09075P1057
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Vimal D. Mehta Ph.D.
Country United States of America
Currency EUR
Employees 0,0 T
Address 555 Long Wharf Drive, 06511 New Haven
IPO Date 2018-03-08

Stock Splits

Date Split
10.02.2025 1:16

Ticker Symbols

Name Symbol
Frankfurt BX2.F
NASDAQ BTAI

More Shares

Investors who BIOXCEL THERAPEUT hold also have the following shares in their portfolio:
ADOBE INC
ADOBE INC Share
AMAZON.CO INC
AMAZON.CO INC Share
AMGEN INC
AMGEN INC Share
AUTODESK INC
AUTODESK INC Share
CISCO SYSTEMS INC
CISCO SYSTEMS INC Share
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Share
DEKA-EUROPA AKT.STRATEGIE
DEKA-EUROPA AKT.STRATEGIE Fund
DWS ESG DYNAMIC OPPORTUNITIES LD
DWS ESG DYNAMIC OPPORTUNITIES LD Fund
EASY
EASY Crypto
INTEL CORP
INTEL CORP Share
INVESTEC BANK PLC IMPALA QUAD INDX 18/08/23
INVESTEC BANK PLC IMPALA QUAD INDX 18/08/23 Bond
NETFLIX INC
NETFLIX INC Share
TESLA INC
TESLA INC Share
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025